Hualan Biological Engineering, Inc.

Pharmaceutical industry · Xinxiang, Henan

About Hualan Biological Engineering, Inc.

Hualan Biological Engineering, Inc. is a Chinese biopharmaceutical company founded in 1992 in Xinxiang, Henan province, and listed on the Shenzhen Stock Exchange. The company is mainly engaged in the research, development, production and sale of human plasma-derived products, vaccines and recombinant protein products obtained through genetic engineering.

In blood products, its catalogue includes human serum albumin, immunoglobulins (intravenous, intramuscular, tetanus and hepatitis B), coagulation factor VIII, prothrombin complex and human fibrinogen, supported by its own network of plasma collection stations. In vaccines, Hualan was the world's first manufacturer to launch a pandemic H1N1 influenza vaccine and produces seasonal influenza vaccines, including one with WHO prequalification, in addition to rabies and ACYW135 meningococcal vaccines.

The company maintains production bases in Xinxiang and a separately listed vaccine subsidiary, together with a growing line of recombinant proteins and antibodies. For international partners, Hualan is one of China's major producers of blood products and vaccines, headquartered in Xinxiang with exports to dozens of countries.

Other businesses in Pharmaceutical industry